LTI 05
Alternative Names: LTI-05Latest Information Update: 27 May 2026
At a glance
- Originator Lung Therapeutics
- Developer Rein Therapeutics
- Class Antifibrotics
- Mechanism of Action Epithelial sodium channel antagonists
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Suspended Cystic fibrosis